HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

Por Andersen, TI, Skovlund, E, Bukholm, IK, Jacobsen, U, Kåresen, R, Erikstein, B, Nesland, J, Børresen-Dale, A-L
Publicado em 2000

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer

Por Langerød, A, Zhao, H, Borgan, Ø, Nesland, JM, Hernandez-Boussard, T, Bukholm, IK, Kåresen, R, Børresen-Dale, AL, Jeffrey, SS
Publicado no Breast Cancer Res (2005)

p16(INK4A) as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy

Por Geisler, S, Smith-Sørensen, B, Betticher, D, Bukholm, IK, Akslen, LA, Kappeler, A, Gugger, M, Lønning, PE, Børresen-Dale, A-L
Publicado em 2000